Key Proteo and Thermo-Fisher find Dynabead success together
Success story
Seattle-based Key Proteo has a simple mission to provide preemptive treatment for genetic diseases before they are clinically manifested by expanding and improving newborn screening programs. Key Proteo is doing this by developing novel proteomic-based newborn screening methods to radically change the course of treatable genetic diseases.
Through their research and development process, Key Proteo teamed up with Thermo Fisher Scientific’s Dynabeads OEM team to manufacture the magnetic beads utilized in their product. Their prior success in using Dynabeads magnetic beads prompted Key Proteo to request a feasibility study by Thermo Fisher in order to explore differences in Dynabeads architecture and chemistry. This study focused on identifying the number of distinct antibodies that could be coupled to the magnetic beads and exploring the different performances of Dynabeads products in the Key Proteo assay. Not only was it important for Key Proteo to identify the amount and number of antibodies that could successfully couple to the bead, but they also needed to understand the cost consequences of varying the number of antibodies, type of beads, conjugation strategy, and any affects to product stability through the entire workflow. These factors were balanced while maintaining the performance and cost effectiveness of Key Proteo’s newborn screening assay.
Thermo Fisher’s expertise in bulk antibody-Dynabeads reagent production as well as their overall expertise in magnetic bead technology has allowed Key Proteo to successfully continue to develop and manufacture their product. Their technology will allow the targeting of new or existing genetic conditions to change their clinical course and ensure a better quality of life for patients.
